JNJ vs NVS stock comparison
Johnson & Johnson vs. Novartis · data as of November 13, 2026
Johnson & Johnson (JNJ) has a market value of about $687.9B, Novartis (NVS) about $306.3B. Over their latest twelve months Johnson & Johnson had revenue of $99.3B and Novartis $57.4B.
On our five checks Johnson & Johnson scores higher: 2.6 out of 5 (average) against 2.0 (weak).
By area, the stronger company is Johnson & Johnson on financial health; Johnson & Johnson on shareholder returns.
Novartis is cheaper on earnings (P/E 30.7 vs. 43.4), while Johnson & Johnson grew revenue faster over five years (2.7% vs. 2.3% a year).
Johnson & Johnson leads on 8 of the compared lines and Novartis on 14.
Side by side
| JNJ | NVS | |
|---|---|---|
| Size and price | ||
| Market cap | $687.9B | $306.3B |
| Share price | $285.75 | $160.50 |
| Score | ||
| Overall score (of 5) | 2.6 | 2.0 |
| Value | 0 | 0 |
| Future growth | 0 | 0 |
| Track record | 4 | 4 |
| Financial health | 4 | 3 |
| Shareholder returns | 5 | 3 |
| Valuation | ||
| P/E (TTM) | 43.4 | 30.7 |
| Forward P/E | 25.1 | 17.0 |
| Price / free cash flow | 33.4 | 21.9 |
| Price / sales | 6.9 | 5.3 |
| EV / EBITDA | 26.7 | 14.4 |
| PEG | 2.91 | 2.02 |
| DCF value vs. price | −39% | −9% |
| Business | ||
| Revenue | $99.3B | $57.4B |
| Net income | $16.1B | $10.0B |
| Free cash flow | $20.6B | $14.0B |
| Net margin | 16.2% | 17.5% |
| Gross margin (5-yr avg.) | 69.1% | 76.4% |
| ROIC (5-yr avg.) | 16.6% | 14.1% |
| Growth | ||
| Revenue growth (1 yr) | 6.0% | 8.4% |
| Revenue growth (5 yrs, per year) | 2.7% | 2.3% |
| EPS growth (5 yrs, per year) | 14.9% | 15.2% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$27.4B | -$39.3B |
| Dividend yield | 1.88% | 2.95% |
| Shareholder yield | 2.8% | 6.0% |
| Analysts | ||
| Upside to average target | −2% | −2% |
| Consensus rating | Buy | Hold |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: JNJ TTM to September 27, 2026, NVS TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Johnson & Johnson or Novartis?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Johnson & Johnson scores 2.6 out of 5 and Novartis 2.0; the table shows where each one is stronger.
Is Johnson & Johnson cheaper than Novartis?
On trailing earnings, Novartis trades at a P/E of 30.7 and Johnson & Johnson at 43.4, so Novartis is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Johnson & Johnson or Novartis?
Over five years Johnson & Johnson grew revenue about 2.7% a year and Novartis about 2.3% a year.
Which pays a higher dividend?
Johnson & Johnson yields 1.88% and Novartis 2.95%.
Full Johnson & Johnson analysis → Full Novartis analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.